TARDBP and amyotrophic lateral sclerosis: The frontal cortex was chosen because it was a likely site for discriminating proteomic differences in ALS patients with and without dementia, and represents an area in which TDP‐43 pathological burden has been mapped in FTD patients (Brettschneider et al, 2014).